Clinical Trial Update: Safety and Efficacy of APL180 in Healthy Volunteers and Patients With Coronary Heart Disease (CHD) [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial update on APL180 assessing safety and efficacy in healthy volunteers and patients with Coronary Heart Disease.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Coronary Heart Disease

Drugs mentioned

• APL180

Snippet

Sponsor: Novartis | Conditions: Coronary Heart Disease | Phase 1, Phase 2 | Status: COMPLETED